Figure 5.
The effect of anti-CD36 on pups’ platelet counts and litter size from Cd36−/− immunized mothers treated with IVIG or deg-32-106 antibodies. (A) Platelets from survivor pups derived from untreated, IVIG-treated (1 g/kg), or deg-32-106–treated (5 mg/kg) mothers were collected and quantified by flow cytometry using counting beads as standard. The pups’ platelets from the untreated group were compared with those from 3 treated groups, including treatment with IVIG after breeding on days 10, 15, and 20; treatment with IVIG on days 7, 12, and 17; and treatment with deg-32-106 after breeding on days 10, 15, and 20. For each group, the platelets of 12 to 29 pups were counted. Data are expressed as mean ± standard deviation. Significance (*P < .05) was analyzed by using a two-tailed unpaired Student t test. (B) The litter size numbers derived from immunized Cd36−/− mothers treated with IVIG (cohort #5b; n = 9) or deg-32-106 (cohort #8; n = 6) were compared with those of untreated Cd36−/− mothers (cohort #3; n = 16). The data were analyzed by one-way analysis of variance, followed by the Bonferroni post hoc test (*P < .05). n.s, not significant.

The effect of anti-CD36 on pups’ platelet counts and litter size from Cd36−/− immunized mothers treated with IVIG or deg-32-106 antibodies. (A) Platelets from survivor pups derived from untreated, IVIG-treated (1 g/kg), or deg-32-106–treated (5 mg/kg) mothers were collected and quantified by flow cytometry using counting beads as standard. The pups’ platelets from the untreated group were compared with those from 3 treated groups, including treatment with IVIG after breeding on days 10, 15, and 20; treatment with IVIG on days 7, 12, and 17; and treatment with deg-32-106 after breeding on days 10, 15, and 20. For each group, the platelets of 12 to 29 pups were counted. Data are expressed as mean ± standard deviation. Significance (*P < .05) was analyzed by using a two-tailed unpaired Student t test. (B) The litter size numbers derived from immunized Cd36−/− mothers treated with IVIG (cohort #5b; n = 9) or deg-32-106 (cohort #8; n = 6) were compared with those of untreated Cd36−/− mothers (cohort #3; n = 16). The data were analyzed by one-way analysis of variance, followed by the Bonferroni post hoc test (*P < .05). n.s, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal